A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults with Tourette Syndrome

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512949-17-00

Acronym

SCI-021-001

Enrollment

Registered

2024-07-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tourette's syndrome in adults (≥18 and ≤65 years) in out-patient care

Brief summary

[CCI]

Detailed description

[CCI], [CCI], [CCI], [CCI], [CCI], [CCI], [CCI], Number of adverse events (AEs), number and rate of patients affected by AEs, SAEs, SUSARs/ADRs, AESIs and AEs leading to withdrawal at each visit., Absolute values of vital signs (blood pressure, heart rate) at each visit and change from baseline for each visit. Number and percentage of clinically significant abnormal values.

Interventions

DRUGSCI-110 Placebo Drug Product

DRUGSCI-110_DF1

DRUGSCI-110_DF3

DRUGSCI-110_DF2

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
[CCI]	—

Secondary

Measure	Time frame
[CCI], [CCI], [CCI], [CCI], [CCI], [CCI], [CCI], Number of adverse events (AEs), number and rate of patients affected by AEs, SAEs, SUSARs/ADRs, AESIs and AEs leading to withdrawal at each visit., Absolute values of vital signs (blood pressure, heart rate) at each visit and change from baseline for each visit. Number and percentage of clinically significant abnormal values.	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026